Abstract | OBJECTIVES: PATIENTS AND METHODS: In 58 patients who received AmBD, circulating serum interleukin (IL)-6, IL-8 and IL-10 were measured at baseline, week 1 and week 2 of antifungal treatment and correlated to the development of renal impairment. The Cox proportional hazards model approach was adopted for analysis. RESULTS: The P value was 0.026 for the overall effect of IL-6 on time to development of AKI. An increasing or non-receding IL-6 trend by week 1 of AmBD treatment (followed by a decreasing or non-receding IL-6 trend from week 1 to week 2) correlated with an increased likelihood of nephrotoxicity [hazard ratio (HR) 6.93, P value 0.005 and HR 3.46, P value 0.035, respectively]. Similarly, persistently increasing IL-8 levels were linked to a 3.84-fold increased likelihood of AKI. CONCLUSIONS: In patients receiving AmBD, persistence of an elevated pro-inflammatory cytokine milieu is associated with a predisposition to drug-related kidney injury.
|
Authors | Louis Y A Chai, Mihai G Netea, Bee Choo Tai, Lay Wai Khin, Alieke G Vonk, Boon Wee Teo, Haran T Schlamm, Raoul Herbrecht, J Peter Donnelly, Peter F Troke, Bart-Jan Kullberg |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 68
Issue 7
Pg. 1655-9
(Jul 2013)
ISSN: 1460-2091 [Electronic] England |
PMID | 23557927
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- IL10 protein, human
- IL6 protein, human
- Interleukin-6
- Interleukin-8
- Interleukin-10
- Amphotericin B
|
Topics |
- Acute Kidney Injury
(chemically induced, immunology)
- Adult
- Aged
- Amphotericin B
(administration & dosage, adverse effects)
- Antifungal Agents
(administration & dosage, adverse effects)
- Female
- Humans
- Interleukin-10
(blood)
- Interleukin-6
(blood)
- Interleukin-8
(blood)
- Male
- Middle Aged
- Serum
(chemistry)
|